Company news

Arbutus Biopharma Corporation news in 2025

Arbutus Biopharma Corporation's news releases, calls and decks from 2025, newest first.

View company

Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 12, 2025

Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025

October 6, 2025

Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 5, 2025

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

June 24, 2025

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 13, 2025

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

May 6, 2025

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

April 22, 2025

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

March 26, 2025

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

March 2, 2025

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

February 25, 2025

Arbutus Provides 2025 Corporate and Financial Update

January 12, 2025

Decks in 2025